Sei Investments Co. Acquires 68,127 Shares of Lumexa Imaging Holdings, Inc. $LMRI

Sei Investments Co. grew its holdings in shares of Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) by 339.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 88,190 shares of the company’s stock after acquiring an additional 68,127 shares during the quarter. Sei Investments Co. owned 0.09% of Lumexa Imaging worth $758,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Assetmark Inc. bought a new stake in shares of Lumexa Imaging during the 4th quarter valued at approximately $36,000. Strs Ohio bought a new position in Lumexa Imaging in the 1st quarter valued at approximately $38,000. Barclays PLC bought a new position in Lumexa Imaging in the 4th quarter valued at approximately $133,000. PNC Financial Services Group Inc. acquired a new stake in Lumexa Imaging in the first quarter valued at approximately $63,000. Finally, Principal Financial Group Inc. boosted its position in Lumexa Imaging by 1.2% in the first quarter. Principal Financial Group Inc. now owns 664,136 shares of the company’s stock valued at $5,712,000 after buying an additional 7,875 shares in the last quarter.

Lumexa Imaging Stock Performance

Shares of Lumexa Imaging stock opened at $12.20 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.40 and a debt-to-equity ratio of 1.43. Lumexa Imaging Holdings, Inc. has a twelve month low of $6.45 and a twelve month high of $19.45. The stock has a market cap of $1.17 billion and a price-to-earnings ratio of -20.68. The company’s fifty day moving average is $10.78 and its 200 day moving average is $10.90.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on LMRI shares. Wall Street Zen downgraded shares of Lumexa Imaging from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Deutsche Bank Aktiengesellschaft set a $16.00 price objective on Lumexa Imaging in a report on Thursday. Weiss Ratings raised Lumexa Imaging from a “sell (e)” rating to a “sell (d)” rating in a report on Thursday, June 25th. Finally, Barclays dropped their target price on Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating for the company in a research report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Insider Buying and Selling

In related news, Director Brett Brodnax bought 35,000 shares of the business’s stock in a transaction on Tuesday, May 19th. The shares were purchased at an average cost of $7.25 per share, with a total value of $253,750.00. Following the acquisition, the director owned 62,027 shares of the company’s stock, valued at $449,695.75. This represents a 129.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.70% of the company’s stock.

About Lumexa Imaging

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).